RxDoctor Payments Data

Budder Siddiqui, MD

Infectious Disease · Gainesville, GANPI 1366670051

Payments from drug & device makers

$1,031in general payments, 2019–2025

Across 44 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$226
  • Insmed, Inc.$217
  • Astellas Pharma US Inc$121
  • AbbVie$99
  • Gilead$93
  • Melinta Therapeutics, LLC$74
  • plus $201 from 7 others

What the payments were for

  • Food & beverage$1,01598%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,031 in reported general payments places this provider in the 45th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$115,628
Medicare patients
477
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala119$504,178
GenvoyaElviteg/Cob/Emtri/Tenof Alafen17$98,134
JulucaDolutegravir/Rilpivirine24$83,673
CresembaIsavuconazonium Sulfate12$71,188
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$50,377
TivicayDolutegravir Sodium22$45,391
ErtapenemErtapenem Sodium54$32,970
Cefepime Hcl75$26,298
Meropenem29$20,362
Linezolid88$9,592
MicafunginMicafungin Sodium16$8,734
Vancomycin Hcl49$8,557
Fluconazole148$6,510
Daptomycin14$4,166
Fosfomycin Tromethamine39$3,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$93$602,312136 claims
Viiv Healthcare CompanyJuluca, Tivicay$226$129,06446 claims
Astellas Pharma US IncCresemba$121$71,18812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →